Welcome to SynapCell

SynapCell is a biotechnology company providing the CNS drug manufacturing industry with translational drug discovery solutions to reveal the therapeutic potential of their molecules targeting CNS disorders.



Epilepsy solutions

Since 2005 SynapCell has been assessing the efficacy of your drug candidates for epilepsy using surface and deep EEG recording. We use a translational approach combining relevant animal models of different types of epilepsy, protocols performed in clinical conditions, and quantitative results to reveal brain dysfunction and epileptic seizures.


Solutions for other CNS disorders

With a translational approach combining relevant animal models of CNS disorders, protocols performed in clinical conditions and EEG-related technologies to reveal brain activities, SynapCell assesses the effects of your drug candidates in the treatment of CNS disorders with unmet needs.


EEG phenotyping of rodent models

Develop your personalized drug discovery tool using SynapCell’s expertise in the EEG phenotyping of rodent models to improve your insights into the relevance of your therapeutic targets in CNS disorders.

What's new

Feedback on Eilat XII from the CEO of SynapCell
August 31 – September 3, 2014

I am just back from Madrid (Spain) where I attended Eilat XII, the conference on anti-epileptic drugs (AEDs). I believe the conference was a success, it brought together people from biotech and pharma industries, clinicians and academics to discuss epilepsy and AEDs, whether already on the market or under development.

The meeting began with an active discussion of the different topics related to pharmacoresistance, which is still a subject of debate. No consensus was reached as both sides of the argument were supported by clinical, academic and industrial experience!

Read more